Healthtech startup Onsurity secures $16M in Series A round

Onsurity, a healthtech company providing monthly, comprehensive employee healthcare to SMEs, MSMEs, startups and growing businesses, has announced that it has secured $16 million in the Series A funding round. Quona Capital and existing investor Nexus Venture Partners led the funding round. The founder and CEO of Clover Healthcare – Vivek Garipalli also participated in the latest round.

Yogesh Agarwal, Founder and CEO of Onsurity, said, “Technology has enabled healthcare to speed up diagnosis and improve patient care, but has largely neglected the issues of tedious and cumbersome benefits access and onboarding. With Onsurity, we have built a system from the ground up that will enable every organisation—regardless of size—to have access to comprehensive yet affordable healthcare and health benefit options that can be selected, customised, and priced in as little as two minutes.”

Ganesh Rengaswamy, Managing Partner and Co-founder at Quona Capital, added, “Though there are several intermediaries offering health insurance and benefits in India, affordable access to healthcare benefits—a critical part of financial resilience—eludes most small businesses and working people. Unlike existing solution providers, Onsurity is a true pioneer for unique health benefits solutions, making healthcare available to millions of SMEs who are traditionally underserved. We are thrilled to partner with team Onsurity.”

“Indian enterprises, especially mid-sized ones, lack easy access to healthcare benefits for their employees and partners. Onsurity is solving this large unmet need with affordable plans and a technology-led approach, from onboarding to supporting medical care,” said Anup Gupta, Managing Director at Nexus Venture Partners.

+ posts

Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of  economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.

What's your take on this post ? Comment: